Amended Statement of Beneficial Ownership (sc 13d/a)
August 05 2013 - 7:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
SCHEDULE 13D
[Rule 13d-101]
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §
240.13d -1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d -2(a)
(Amendment No. 6)*
CHINA BIOLOGIC PRODUCTS, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.0001 PER SHARE
(Title
of Class of Securities)
16938C106
(CUSIP Number)
18th Floor, Jialong International Building, 19 Chaoyang Park
Road
Chaoyang District, Beijing 100125
People's Republic of China
(+86) 10-6598-3111
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)
August 2, 2013
(Date of Event Which Requires
Filing of this Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of §§ 240.13d -1(e), 240.13d -1(f) or
240.13d -1(g), check the following box [ ].
CUSIP No. 16938C106
|
13D
|
Page 2 of 5 pages
|
1.
|
NAMES OF REPORTING
PERSONS
Lin Ling Li
|
2.
|
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS
PF
|
5.
|
CHECK BOX IF DISCLOSURE
OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
[ ]
|
6.
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
People's Republic of China
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
8.
|
SHARED VOTING POWER
0
|
9.
|
SOLE DISPOSITIVE POWER
0
|
10.
|
SHARED DISPOSITIVE POWER
0
|
11.
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
|
12.
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[ ]
|
13.
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
0
|
14.
|
TYPE
OF REPORTING PERSON
IN
|
CUSIP No. 16938C106
|
13D
|
Page 3 of 5 pages
|
This Amendment No. 6 (this
Amendment) to Schedule 13D amends the previous Schedule 13D filed by the
Reporting Person with the SEC on September 13, 2007, as amended by Amendment No.
1 filed with the SEC on June 25, 2010, as amended by Amendment No. 2 filed with
the SEC on September 3, 2010, as amended by Amendment No. 3 filed with the SEC
on December 14, 2010, as amended by Amendment No. 4 filed with the SEC on March
19, 2012, as amended by Amendment No. 5 filed with the SEC on May 1, 2013
(collectively as amended, the Original 13D), relating to the Common Stock of
China Biologic Products, Inc., a Delaware corporation (the Issuer). Except as
amended and supplemented herein, the information set forth in the Original 13D
is unchanged and has been omitted from this Amendment No. 6. Capitalized terms
used herein without definition have meanings assigned thereto in the Original
13D.
ITEM 2. Identity and Background.
Item 2(c) is hereby amended as follows:
(c) Ms. Li is a shareholder and
director of Happy Will Industrial Limited which is incorporated under laws of
Hong Kong and principally engages in investment. The business address of Happy
Will Industrial Limited is Room 1105, Lippo Center, Tower 2, 89 Queensway,
Admiralty, Hong Kong.
ITEM 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby supplemented as follows:
The disclosure contained in Item
4 is hereby incorporated herein by reference.
ITEM 4. Purpose of Transaction.
Item 4 is hereby supplemented as follows:
On August 2, 2013, the Reporting
Person and her husband entered into a redemption agreement with the Issuer (the
Redemption Agreement), providing for the sale of all of the Reporting Persons
shares of Common Stock to the Issuer in exchange for cash payment (the Sale).
Pursuant to the Redemption Agreement, at the effective time of the Sale, the
Issuer has agreed to repurchase all 1,479,704 shares of Common Stock (the
Redeemed Shares) held by the Reporting Person for an aggregate purchase price
of US$29,594,080 (the Redemption Price).
At the closing of the redemption,
US$11,837,632 out of the Redemption Price will be paid to the representative of the
plaintiffs of certain pending lawsuit filed in the High Court of Hong Kong (the
HK Lawsuit) against the Reporting Person, her husband and certain other
defendants to settle the title dispute between such plaintiffs and the Reporting
Person and her husband in respect of the Redeemed Shares.
CUSIP No. 16938C106
|
13D
|
Page 4 of 5 pages
|
The description of the Redemption
Agreement contained in this Item 4 is not intended to be complete and is
qualified in its entirety by reference to such agreement, filed as an exhibit
hereto and incorporated by reference herein.
ITEM 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated in its entirety as
follows:
The disclosure contained in Item
4 is hereby incorporated herein by reference.
As of August 2, 2013, the
Reporting Person ceased to be the beneficial owner of any shares of the Issuers
Common Stock.
ITEM 6. Contracts, Arrangements, Understandings or
Relationships With Respect to Securities of the Issuer.
Item 6 is hereby supplemented as follows:
The disclosure contained in Item
4 is hereby incorporated herein by reference.
ITEM 7. Materials to be Filed as Exhibits.
CUSIP No. 16938C106
|
13D
|
Page 5 of 5 pages
|
SIGNATURE
After reasonable inquiry and to
the best of my knowledge and belief, I hereby certify that the information set
forth in this statement is true, complete and correct.
Dated: August 5, 2013
|
LIN LING LI
|
|
|
|
By:
/s/ Lin Ling
Li
|
|
Name: Lin Ling Li
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Sep 2024 to Oct 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Oct 2023 to Oct 2024